5PSQ-034 Evaluation of antibiotics consumption in the intensive care unit of a second-level hospital

<h3>Background and Importance</h3> Intensive care units (ICU) are favourable setting for the development of intra-hospital infections due to antibiotic-resistant bacteria. Therefore, it is necessary to ensure adequate antibiotic treatment by knowing the resistance profile of the microorganisms. <h3>Aim and Objectives</h3> The aim of this study was to analyse the evolution of antibiotic consumption (AC) and microorganisms isolated (MI) in the ICU over the last 3 years. <h3>Material and Methods</h3> This observational and retrospective study was carried out in the ICU of a second-level hospital between 2020 and 2023. To express the AC was used the defined daily dose per 100 stays and day (DDD/100 e-d). AC data were obtained through the electronic prescription program and the MI were provided by the Microbiology Department. For the statistical analysis, STATA-MP-16.0 was used: a correlation matrix was made by evaluating each pair of antibiotics and the Pearson correlation coefficient (CoefP) was calculated applying a multiple linear regression model. <h3>Results</h3> Sixteen active substances (J01 group) were included. The distribution of AC per year in this unit expressed in DDD/100 e-d was 152.97 (2020), 152.11 (2021), 139.85 (2022) and 157.88 (2023). There was a decrease in consumption in 2022 compared to previous years. However, in 2023 there was a rise associated with an increase in intravenous levofloxacin, linezolid, meropenem, tigecycline and vancomycin. Consumption of meropenem was high in all years while piperacillin/tazobactam remained low. Results from the statistical study showed a positive correlation between the increased consumption of intravenous amoxicillin/clavulanic acid, tigecycline and linezolid (CoefP: 0.948, p_value: 0.0126). When linear regression was applied, the relationship between three drugs was statistically significant (R2=98.76, p_value: 0.0434). The MI in this unit between 2020 and 2023 were: 28% extended-spectrum beta-lactamase-producing E. coli (BLEE+), 26% methicillin-resistant Staphylococcus aureus (MRSA), 13% K. pneumoniae BLEE+, 12% P. aeruginosa and other microorganisms. <h3>Conclusion and Relevance</h3> Analysis using DDD/100 e-d allows comparisons between the years of the study. These results of AC are matched with the MI. Knowing these consumption trends, measures can be taken in the following years to promote rational and safe use of antibiotics. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest